IMR Press / CEOG / Volume 45 / Issue 4 / DOI: 10.12891/ceog4340.2018

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Case Report
Treatment using tadalafil for dichorionic diamniotic twin pregnancy with fetal growth restriction
Show Less
1 Department of Obstetrics and Gynecology, Mie University School of Medicine, Mie, Japan
2 Department of Pathology, Mie University School of Medicine, Mie, Japan
Clin. Exp. Obstet. Gynecol. 2018, 45(4), 591–593;
Published: 10 August 2018

Fetal growth restriction (FGR) is the most important cause of perinatal morbidity and mortality in developed countries. Clinicians are often forced to end the pregnancy due to fetal indications, inflicting iatrogenic prematurity on a fetus with associated high risk of adverse neonatal outcomes. Here, the authors report a case of dichorionic diamniotic (DD) twin pregnancy with FGR whose pregnancy was successfully prolonged using tadalafil, a phosphodiesterase 5 inhibitor. A 22-year-old primigravid woman presented at 25 5/7 weeks of gestation with DD twin pregnancy with FGR. Tadalafil administration was begun at this time. Her pregnancy was prolonged by 90 days after initiation of tadalafil. Tadalafil may be a novel treatment to prolong the period of pregnancy in cases of DD twin pregnancy with FGR and threatened premature labor.
Dichorionic diamniotic twin pregnancy
Fetal growth restriction
Threatened premature labor
Back to top